Perrigo — Third Quarter 2026 Earnings Summary

Perrigo reported a third quarter 2026 net loss of $27.5 million with reported diluted earnings per share of $(0.20), driven by a $4.1 million impairment charge and lower sales volumes. The company announced an agreement to divest its Infant Formula business for up to $175 million, a move expected to result in an impairment loss between $275 million and $375 million in the fourth quarter. Adjusted diluted earnings per share for the quarter was $0.60 on an All-In basis and $0.61 on a Core basis, reflecting a 25% and 9% decline respectively compared to the prior year. Perrigo updated its full-year 2026 outlook to exclude the Infant Formula business, citing measured retailer inventory positioning and continued softness in the European market.